Therapeutic Approach

Press Releases / News


December – Ritter Pharmaceuticals Enters Into a $10 Million Common
Stock Purchase Agreement with Aspire Capital Fund

November – Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update

October – Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board

October – Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer

October – Ritter Pharmaceuticals to Present at the 2015 Aegis Growth Conference

September – Ritter Pharmaceuticals to Present at the 3rd Microbiome R&D Business Collaboration Forum

August – Ritter Pharmaceuticals Retains William M. Merino as Senior Clinical and Regulatory Advisor

June – Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering

April – Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors

April – Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors

February – Ritter Pharmaceuticals Names Matthew W. Foehr to its Board of Directors


September – Ritter Pharmaceuticals Names Michael D. Step Chief Executive Officer

May – Andrew Ritter Named Finalist for 2nd Consecutive Year in LA Business Journal’s Annual Healthcare Leadership Awards

January – Ritter Pharmaceuticals Announces Publication of Lactose Intolerance Phase 2 Trial in Nutrition Journal


October – Using Galacto-Oligosaccharides to Improve Lactose Tolerance: Food Technology

June – Ritter Pharmaceuticals’ Study Shows That Altering the Intestinal Microbiome May Offer an Effective Treatment for Lactose Intolerance

April – Andrew Ritter Named Finalist in LA Business Journal’s Annual Healthcare Leadership Awards

April – Patient Survey: More than 80% Forced to Change Lifestyles Due to Lactose Intolerance

March – Ritter Pharmaceuticals Encouraged by Meeting with FDA

February – Ritter Pharmaceuticals Names Larry Good, M.D. Chief Medical Officer

January – Survey: 75% of People with Lactose Intolerance Avoid Dairy Food

January – Lactose Intolerance: Major Unmet Medical Need



July – Ritter Pharmaceuticals Appoints Michael Step to the Board of Directors

May – Ritter Pharmaceuticals Presents Its Phase 2 Study of RP-G28 at Digestive Disease Week 2012

February – Ritter Pharmaceuticals’ Abstract on RP-G28’s Phase 2 Trial Selected for Oral Presentation at Digestive Disease Week 2012

January – Ritter Pharmaceuticals’ RP-G28 Improves Lactose Intolerance Symptoms and Lactose Digestion in Phase 2 Trial



December – Ritter Pharmaceuticals Appoints Robert H. Tidwell as Chief Business Officer

November – Ritter Pharmaceuticals Completes Phase 2 Trial for Lactose Intolerance

June – Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance



November – Ritter Pharmaceuticals, Inc. Awarded a Grant under the U.S. Qualified Therapeutic Discovery Project Program

October – Ritter Pharmaceuticals, Inc. Wins Top Awards at Venture Capital Investment Competition

October – Ritter Pharmaceuticals Wins 2010 San Diego Quick Pitch Competition

June – Ritter Pharmaceuticals, Inc. Receives FDA IND Approval For Lactose Intolerance Treatment

February – Ritter Pharmaceuticals, Inc. to Discuss Lactose Intolerance and Associated Health Risks at NIH Conference



September – Ritter Pharmaceuticals’ CEO, Andrew Ritter to Present at the 11th Annual SoCalBio Investor Conference

September – Ritter Pharmaceuticals, Inc. hires Dr. Howard Foyt as Exec VP, Development & Chief Medical Officer

Featuring Recent Posts WordPress Widget development by YD